pipette
ESEspañol

Rewiring dendritic cell function with CLEC9A and DEC205 CARs

Congyi Niu, Xiaoqiu Dai, He Gao, H Zhang, Yunju Ma, Hui Wang, Zhen Xiao, Yingxi Xu, Sudan He, Sudan He, Xiaowen Tang, Peng Lin, Peng Lin, Mikaël J. Pittet, Lianjun Zhang, Chen Wang

Peer-reviewed journalBold claims, read criticallyReal-world use

In the authors' words

Abstract Dendritic cells (DCs) are central orchestrators of anti-tumor immunity, yet their therapeutic utility has been limited by dysfunction and insufficient activation within solid tumors. Here, we report chimeric antigen receptor-engineered DCs (CAR-DCs) that potently prime T cells and reprogram the tumor microenvironment. We identify the intracellular domains of CLEC9A or DEC205 as essential for functional CAR-DC activity, enabling enhanced antigen uptake, cross-presentation, and robust cytokine production that drive strong T cell expansion and effector differentiation. Mechanistically, CARs incorporating CLEC9A or DEC205 intracellular domains triggered SYK phosphorylation and downstream signaling pathways. In both murine and humanized models, CAR-DC therapy suppressed tumor growth and promoted expansion of tumor-reactive T cells. These findings establish CAR-DCs as a scalable and clinically translatable platform for next-generation solid tumor immunotherapy.

Main resultThe abstract does not state a limitation.

Appeared: Sunday, November 15. Nature Immunology. Peer-reviewed journal.

DOI: 10.1038/s41590-026-02711-3